What is Lifesci Capital’s Estimate for IKT FY2025 Earnings?

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Stock analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of Inhibikase Therapeutics in a research note issued to investors on Monday, February 23rd. Lifesci Capital analyst G. Maini expects that the company will earn ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics’ Q4 2025 earnings at ($0.12) EPS.

A number of other research firms also recently weighed in on IKT. Jefferies Financial Group restated a “buy” rating on shares of Inhibikase Therapeutics in a research report on Monday, December 29th. Bank of America started coverage on Inhibikase Therapeutics in a research report on Wednesday, January 21st. They set a “buy” rating and a $6.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Inhibikase Therapeutics in a research report on Friday, December 26th. Finally, Cantor Fitzgerald began coverage on shares of Inhibikase Therapeutics in a research report on Thursday, December 11th. They set an “overweight” rating and a $4.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Inhibikase Therapeutics has a consensus rating of “Buy” and a consensus target price of $6.00.

Inhibikase Therapeutics Stock Performance

NYSE IKT opened at $2.14 on Thursday. Inhibikase Therapeutics has a 52-week low of $1.33 and a 52-week high of $2.58. The company has a fifty day moving average of $1.75 and a 200-day moving average of $1.65. The company has a market capitalization of $160.87 million, a P/E ratio of -0.80 and a beta of 0.84.

Institutional Investors Weigh In On Inhibikase Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in Inhibikase Therapeutics by 277.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company’s stock worth $364,000 after acquiring an additional 122,073 shares during the last quarter. Jane Street Group LLC bought a new stake in Inhibikase Therapeutics in the first quarter valued at approximately $255,000. Geode Capital Management LLC boosted its stake in shares of Inhibikase Therapeutics by 228.5% during the second quarter. Geode Capital Management LLC now owns 1,066,700 shares of the company’s stock valued at $2,080,000 after purchasing an additional 741,940 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Inhibikase Therapeutics in the second quarter worth approximately $34,000. Finally, Intech Investment Management LLC purchased a new position in shares of Inhibikase Therapeutics in the second quarter worth $61,000. Institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases.